

Review

Open Access



Drug resistance and minimal residual disease in multiple myeloma

Alessandro Gozzetti, Sara Ciofini, Anna Sicuranza, Paola Pacelli, Donatella Raspadori, Emanuele Cencini, Dania Tocci, Monica Bocchia

Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena 53100, Italy.

Correspondence to: Prof. Alessandro Gozzetti, Hematology, University of Siena, Policlinico Le Scotte, Viale Bracci 16, Siena 53100, Italy. E-mail: gozzetti@unisi.it

How to cite this article: Gozzetti A, Ciofini S, Sicuranza A, Pacelli P, Raspadori D, Cencini E, Tocci D, Bocchia M. Drug resistance and minimal residual disease in multiple myeloma. *Cancer Drug Resist* 2022;5:171-83. <https://dx.doi.org/10.20517/cdr.2021.116>

Received: 1 Nov 2021 **First Decision:** 5 Jan 2022 **Revised:** 17 Jan 2022 **Accepted:** 29 Jan 2022 **Published:** 16 Feb 2022

Academic Editors: Godefridus J. Peters, Fatih M. Uckun **Copy Editor:** Yue-Yue Zhang **Production Editor:** Yue-Yue Zhang

Abstract

Great progress has been made in improving survival in multiple myeloma (MM) patients over the last 30 years. New drugs have been introduced and complete responses are frequently seen. However, the majority of MM patients do experience a relapse at a variable time after treatment, and ultimately the disease becomes drug-resistant following therapies. Recently, minimal residual disease (MRD) detection has been introduced in clinical trials utilizing novel therapeutic agents to measure the depth of response. MRD can be considered as a surrogate for both progression-free and overall survival. In this perspective, the persistence of a residual therapy-resistant myeloma plasma cell clone can be associated with inferior survivals. The present review gives an overview of drug resistance in MM, i.e., mutation of $\beta 5$ subunit of the proteasome; upregulation of pumps of efflux; heat shock protein induction for proteasome inhibitors; downregulation of *CRBN* expression; deregulation of *IRF4* expression; mutation of *CRBN*, *IKZF1*, and *IKZF3* for immunomodulatory drugs and decreased target expression; complement protein increase; sBCMA increase; and BCMA down expression for monoclonal antibodies. Multicolor flow cytometry, or next-generation flow, and next-generation sequencing are currently the techniques available to measure MRD with sensitivity at 10^{-5} . Sustained MRD negativity is related to prolonged survival, and it is evaluated in all recent clinical trials as a surrogate of drug efficacy.

Keywords: Multiple myeloma, minimal residual disease, drug resistance, therapy, next-generation flow cytometry



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



INTRODUCTION

Multiple myeloma (MM) represents the second most frequent hematological malignancy, and significant survival improvements in the years have been seen^[1-3]. Survival has ameliorated thanks to the availability of novel classes of drugs such as proteasome inhibitors (PIs: bortezomib, and carfilzomib), immunomodulatory drugs (IMiDs: thalidomide, lenalidomide, and pomalidomide), monoclonal antibodies (moAb: daratumumab, elotuzumab, isatuximab, and belantamab mafodotin). These new drugs are utilized alone or combined as triplets or quadruplets in the treatment of relapsed/refractory patients and thereafter at diagnosis with good results also in extramedullary MM^[4-17]. MM has important clinical heterogeneity and complex genetic abnormalities^[18]. Cytogenetic analysis and fluorescence *in situ* hybridization can help to distinguish different categories and risk-stratify MM patients^[19]. In particular, t(4;14), t(14;20), gain of chromosome 1q, and deletion 17p give a poorer outcome, while t(11;14) and t(14;16) seem to have an intermediate prognosis^[20-22]. In this view, relapses are seen in the majority of patients, and some of them still have a dismal prognosis. However, while cytogenetic analysis can help to stratify prognosis, it does not fully explain initial MM drug resistance (DR). Two main factors seem to emerge: (1) acquired drug resistance; and (2) sub-clonal heterogeneity^[23,24]. Mechanisms of acquired drug resistance to the main classes of new drugs available in MM have been extensively reviewed recently^[22]. A novel method to detect minimal residual disease has been developed recently^[23-35], i.e., MRD detected by next-generation flow (NGF) or next-generation sequencing (NGS), which have been reported as important tools by the International Myeloma Working Group (IMWG) in the recent response guidelines^[36]. MRD is an important surrogate for survival, as well as progression-free (PFS) and overall survival (OS)^[37]. In particular, sustained MRD negativity confirmed at one year is of great importance to predict clinical outcome of MM patients. MRD can also detect sub-clones that acquire higher genomic instability and can ultimately drive resistance^[38]. This review summarizes the main DR cell-inherent/intrinsic and extrinsic mechanisms to novel drugs in MM and will focus on recent developments regarding MRD as a tool to predict PFS and OS in clinical trials.

Drug resistance in MM

Drug resistance is the leading cause of a relapsed/refractory disease, and it can ultimately decrease survival. Many novel drugs are now available in MM with many used at diagnosis in triplet or quadruplet. MM patients can develop DR after a few cycles of therapy in a variable manner. The main mechanisms of resistance to chemotherapeutic drugs in MM can involve a drug-efflux pump, such as P-glycoprotein, or other mechanisms that inhibit the drug to enter the cell. Moreover, enzymatic inactivation of the drug or adhesion to bone marrow stromal cells, such as fibroblasts and immune cells including macrophages, in the microenvironment can be mentioned. To develop strategies for the future treatment of DR-MM patients, the main mechanisms of resistance to the different classes of drugs, namely proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, have to be elucidated. The principal mechanisms of resistance to novel drugs and resistance escape are reported in [Table 1](#).

Drug resistance to proteasome inhibitors

The PIs used in recent years in clinical practice are bortezomib (Bor), carfilzomib (Car), and ixazomib (Ixa)^[39,40]. Bor is approved for use at diagnosis in both transplant and non-transplant eligible MM patients, while Car and Ixa are used in the relapsed and refractory treatment setting. The structure of the proteasome was first described as a hollow single-cylinder protein. The proteasome functions as an ATP-dependent organelle in which almost 90% of intracellular proteins are degraded following tagging by the polyubiquitin chain. Three subunits of the proteasome are recognized as the site of degradation in the 20S particle: β 1 (caspase), β 2 (trypsin), and β 5 (chymotrypsin). The final result of proteasome inhibition is MM plasma cell death or apoptosis via protein accumulation^[41]. Other mechanisms have been reported: p53 activation, inhibition of nuclear factor- κ B (NF- κ B) activity, activation of c-Jun N-terminal kinase, and stabilization of cell cycle inhibitors. PI can bind the β 5 subunit reversibly (Bor and Ixa) or irreversibly (Car). Resistance to

Table 1. Principal mechanisms of drug resistance and resistance escape

C	D	M of A	DR	Resistance escape	Ref.
moAb	Dara Isa Elo Bela	ADCC, CDC, macrophage-mediated phagocytosis, apoptosis via Fc-mediated crosslinking stimulatory effects on NK cells (for anti CD38 moAb), direct cytotoxicity	Decrease target expression, complement protein increase, sBCMA increase, BCMA down expression	Change drug class, upregulation of CD38 using ATRA	[61-67]
IMiDs	Tha Lena Poma	BM microenvironment targeting; degradation of <i>IKZF1</i> and <i>IKZF3</i> via <i>CRBN</i> -dependent ubiquitination; <i>IRF4</i> and <i>MYC</i> downregulation; triggering caspase 8/9-mediated apoptosis; immune modulation; anti-angiogenic activity	Downregulation of <i>CRBN</i> expression; deregulation of <i>IRF4</i> expression Mutation of <i>CRBN</i> and <i>IKZF1</i> and <i>IKZF3</i>	Change drug class, next-generation <i>CRBN</i> E3 ligase modulators (iberdomide)	[58,59]
PIs	Bort Car Ixa	Inhibition of activity of the 20S proteasome; inhibition of NF- κ B activity; induction of apoptosis by activation of caspase 8/9 and p53; adhesion molecules downregulation	Mutation of β 5 subunit, upregulation of pumps of efflux, HSP induction	Change drug class, pan proteasome inhibitor (marizomib), hydroxychloroquine, pan HDAC inhibitor	[46,48]

C: Class of drug; D: drug name; M of A: mechanisms of action; DR: drug resistance; moAb: monoclonal antibody; IMiDs: immunomodulatory drug; PI: proteasome inhibitors; Dara: daratumumab; Isa: isatuximab; Elo: elotuzumab; Bela: belantamab mafodotin; Tha: thalidomide; Lena: lenalidomide; Poma: pomalidomide; Bor: bortezomib; Car: carfilzomib; Ixa: ixazomib; ADCC: antibody-dependent cellular cytotoxicity; CDC: complement-dependent cytotoxicity; BCMA: b cell maturation antigen; ATRA: all trans retinoic acid; *IKZF1*: Ikaros; *IKZF3*: Aiolos; BM: bone marrow; *CRBN*: Cereblon; *IRF4*: interferon regulatory factor 4; NF- κ B: nuclear factor- κ B; HDAC: histone deacetylase; HSP: heat shock protein.

PIs is related to mutations in the β 5 subunit gene (*PSMB5*) at both diagnosis and relapse^[42,43]. The presence of mutations at other subunits, namely *PSMA1*, *PSMB8*, and *PSMB9*, has been described, but they have not been found to be related to resistance yet and thus need to be confirmed. Another protein important for DR seems to be the X-box protein 1 that acts in the proteostasis in the MM plasma cell. Downregulation of this pathway has been reported in PI-DR cells^[44]. Decreased drug accumulation is another mechanism of DR in MM. In particular, the multidrug resistance protein P-glycoprotein (P-gp) has been well studied in the past^[45]. P-gp works by implementing drug efflux from the MM plasma cell, thus reducing drug activity. Both Car and Bor have been reported to be P-gp substrates^[46-48]. The mechanisms of resistance escape are reported in Table 1^[49,50]. The results of preclinical studies indicate that inhibition of various heat shock proteins (HSPs), e.g., HSP90, can increase the efficacy of PIs^[51]. HSPs are induced by the transcriptional blockade of protein degradation, which can contribute to drug resistance. The results from early phase I trials combining HSP90 inhibitors with PIs have identified safe doses for both drugs. In a preclinical study using bor-resistant MM cell lines, the blockade of IGF-1 downstream effectors re-sensitized cell lines to bortezomib. Furthermore, the IGF-1R inhibitor OSI-906 induced more apoptosis than Bor alone, both *in vitro* and *in vivo*^[52].

Moreover, investigators used a mouse MM model to study gene-expression signatures (GES) related to Bor resistance. GES related to resistance included nuclear factor (erythroid-derived 2)-like 2 (*NFE2L2*), highly expressed as part of an antioxidant-response pathway^[53]. Thus, MM cells with elevated antioxidant capacity before treatment might be resistant to bortezomib.

Drug resistance to immunomodulatory drugs

The IMiDs currently used in clinical practice are thalidomide, lenalidomide, and pomalidomide (Thal, Len, and Pom, respectively). All three agents were initially used in the relapsed and refractory setting, but Len and Thal are now also approved for use at diagnosis^[54]. IMiDs have antiproliferative properties and direct pro-apoptotic effects. Other mechanisms exhibited are anti-angiogenic and immunomodulatory effects, by activating NK and T cells. The E3 ligase protein Cereblon (*CRBN*) is targeted by IMiDs, in particular in complex with CRL4, ultimately leading to degradation of the Aiolos and Ikaros proteins and *IRF4* reduction^[55-57]. This mechanism of action is the principal target of DR, mainly because of occurring mutations or gene expression modifications in this complex. It has been demonstrated that *CRBN* mutations appear after a relapsed/refractory disease occurs, probably due to clonal selection after long IMiD therapy^[58]. In addition, *IRF4* has been investigated as a potential downstream target for DR in Waldenstrom macroglobulinemia after therapy with Len and Pom^[59]. Methylation of *CRBN* has also been recently reported^[60].

Drug resistance to monoclonal antibodies

Monoclonal antibodies directed at antigens present on the surface of plasma cells have recently entered the therapeutic armamentarium against MM. The approved moAb in clinical practice are daratumumab, elotuzumab, isatuximab, and belantamab mafodotin. These drugs were all tested as monotherapy first, and have since been proven to be more efficacious when combined with other agents in triplet or quadruplet^[61-65].

Even though daratumumab, an IgG 1 anti-CD38 moAb, has been found to be very efficacious, resistance can be observed during treatment. Although CD38 mutations are not described as potential mechanism of DR, it has been reported that low CD38 expression could be a cause of initial resistance to therapy. Moreover, CD38 expression reduction during treatment has been described as a major mechanism and occurs via the action of sheddases^[66]. Another occurring event observed is upregulation of CD55 and CD59 complement inhibitors^[67]. For other moAb, the DR mechanism is not currently known, although it is logical to think that, as per daratumumab, the loss of the target antigen is likely a major mechanism of resistance^[68-72].

Extrinsic mechanisms of drug resistance

The bone marrow microenvironment, including osteoblasts, osteoclasts, mesenchymal stem cells (MSC), and tumor-associated macrophages (TAM), is highly connected with MM progression and drug resistance [Figure 1]. In MM in the “osteoblastic niche”, macrophages are differentiated into osteoclasts by the release of osteoclasts activating factors (i.e., IL-6, IL-1- α , TNF- α , TNF- β , and IL-11) and promote bone resorption. Osteoprotegerin represents an antiapoptotic MM factor by binding to TNF-related apoptosis-inducing ligand. Stromal cells can give drug resistance by TGF- β inhibition of osteoblasts differentiation. Stromal cells in the microenvironment have been shown to secrete several cytokines that regulate the antiapoptotic members of the Bcl-2 family (Mcl-1, Bcl-xl, and Bcl2) via IL-6 signaling^[73]. A “vascular niche” is formed by endothelial cells (EC), MSC, and TAM and can protect MM plasma cells from cytotoxic drugs. In particular, EC can express an aberrant active phenotype (VEGFR-2 and FGFR-3) that can help to prevent MM apoptosis, favoring PC migration into the bloodstream and dissemination^[74]. MSC can contribute to bortezomib resistance in MM via Bcl2 increased expression and enhanced NF- κ B activity through cell-cell contact^[74].

TAM have a basic role in MM pathogenesis, since they promote plasma cells proliferation, homing, and angiogenesis, supporting MM immune evasion and progression^[75].




Figure 1. Drug resistance intrinsic and extrinsic mechanisms. EC: Endothelial cells; MSC: mesenchymal stem cells; TAM: tumor-associated macrophages.

MM plasma cells *in vitro* could upregulate CD206 expression and favor an M2 TAM polarization of cocultured macrophages^[76]. In a preclinical model, CD68-positive TAM were shown to inhibit drug-induced apoptosis of tumor cells by caspase 3 and poly-ADP ribose polymerase cleavage^[77,78]. Moreover, intracellular adhesion molecule-1 (ICAM-1) and P-selectin glycoprotein ligand-1 (PSGL-1) on the MM cells surface could activate TAM and favor TAM-induced chemoresistance through the *SRC*, *ERK1/2*, and *C-MYC* pathway^[79]. VEGF production by M2 TAM was demonstrated during progression from MGUS to MM, with increased angiogenic switch^[80,81].

An interesting study reported a possible correlation between the pro-tumor effect of TAM and the Stat3 pathway activation in 5T33MM cells. Interestingly, an ATP-competitive Janus kinase (*JAK*)2 inhibitor, the so-called AZD1480, could restore the sensitivity of MM cells to bortezomib^[82,83].

Clinical studies confirmed CD68/CD163 double-positive M2 TAM were associated with increased microvessel density and reduced survival, independently of the MM stage^[84-86]. In this field, high IHC CD163-positive M2 TAM expression at diagnosis was associated with lower complete response (CR) rate and reduced PFS and OS in 198 MM patients receiving bortezomib-based regimens^[84]. Interestingly, an elevated level of soluble M2 TAM markers CD163 and CD206 was associated with worse OS; conversely, higher M1 density demonstrated a correlation with OS improvement^[85].

In a retrospective study enrolling 68 MM patients, an elevated CD68-positive and CD163-positive TAM expression showed a significant reduction of six-year OS, as confirmed by multivariate analysis. As a

complementary finding, an increased CD163-positive M2 TAM number was associated with an elevated microvessel density^[86]. In another relevant study, a reduced response was observed in patients presenting with high CD68-positive and CD163-positive TAM; however, only high CD163 TAM expression was related to a reduced PFS and OS. CD163 and CD168 were combined with ISS to design a new prognostic model^[87]. M2 TAM infiltration and correlation with pro-angiogenic factor CD147 were investigated in a spectrum from MGUS to recurrence MM. CD163 was used as the M2 marker and the cutoff for M2 infiltration was 100 per core. The authors showed a significant OS reduction in relapsed MM patients with high M2 expression (32 months *vs.* 6 months, $P = 0.02$), suggesting a prognostic role of CD163-positive TAM in MM^[88]. Finally, Andersen *et al.*^[89] evaluated CD163 as a soluble marker in 104 blood samples and 17 BM samples in newly diagnosed MM patients. CD163 BM expression was higher compared to blood samples and was associated with a higher ISS stage. An elevated CD163 expression, with the suggested cutoff of 1.8 mg/L, was associated with poor prognosis, further suggesting M2 TAM could favor MM growth and progression^[89].

MINIMAL RESIDUAL DISEASE

New drugs in MM have revolutionized the treatment paradigm and improved both progression-free and overall survival. However, progress in the definition of response is needed, since a CR has been defined for almost 15 years simply as the absence of a monoclonal component at immunofixation and a percentage of monoclonal plasma cells < 5% in the bone marrow.

The goal is to predict patients relapsing soon after the initial therapy and distinguish them from patients who maintain a long response (sustained CR) that is a surrogate for PFS and OS. Novel drugs are combined now in triplet or quadruplet treatment schedules and can implement in a high percentage of patients CR to a virtual disease disappearance. However, most MM patients still relapse. NGF and NGS have been introduced into clinical trials, bringing more sensitivity to detect minimal residual disease after therapy^[23-34]. The detection limit of MRD is now considered 10^{-5} ; however, data suggest that a deeper limit of 10^{-6} or 10^{-7} could predict a better PFS^[90]. Although NGS has been reported initially to have a deeper limit of detection (10^{-6}) than NGF (10^{-5}), both can now reach comparable sensitivity at 10^{-6} .

NGF and NGS in MM

NGF has recently become part of the MRD evaluation, and it is based on the detection and quantification of normal PC *vs.* monoclonal PC using specific antibodies: PC markers such as CD38 and CD138; aberrant antigens expression such as CD45^{-low}, CD19⁻, CD27⁻, CD81⁻, and CD56; CD28; CD117; and light chains κ or λ . The Euro-Flow Consortium has introduced a more sensitive standardized technique based on two eight-color tubes that permit detecting MRD with 100% applicability^[24] with a 4 h sample processing time. Sensitivity needs to be at least 10^{-5} , but it has been reported as even better. A correct and adequate concentrate sample is needed to avoid hemodilution, and strategies to overcome CD38 monoclonal antibody interference have been described^[26].

NGS analyzes the clonal rearrangements of the immunoglobulin heavy chain (IgH) regions with parallel sequencing of reads with a sensitivity of 10^{-6} . Importantly, patient primer construction is not needed, and the depth of detection is a strength^[91]. Commercial kits are now available and FDA approved (LymphoSIGHT[®] and ImmunoSEQ, Adaptive Biotechnologies). Costs and a bioinformatic database for analysis as well as hemodilution are the limits^[26]. NGF and NGS are recognized as complementary techniques, and the IMWG suggests utilizing the one available at the centers in clinical trials^[36]. The Cassiopeia trial showed comparable sensitivity for NGF and NGS^[13].

Minimal residual disease sub-clone characterization

MRD can be a surrogate for PFS and OS and is becoming an important tool for risk-stratification since the depth of response is correlated with prolonged survival^[92]. In fact, a non-sustained CR can frequently be seen in MRD-positive MM patients. A goal in actual MM therapy could be to reach a sustained CR with MRD negativity lasting for at least one year. Searching for a sub-clone in MRD analysis could be an ideal way to identify drug resistance. It has been reported that MRD MM sub-clones could overexpress CD11a, CD11c, CD29, CD44, CD49d CD49e, CD54, CD138, CXCR4, and HLADR in the GEM2010MAS65 study involving 40 elderly patients^[93] treated with nine cycles of VMP (bortezomib, melphalan, and prednisone) or alternating VMP to Rd (lenalidomide and dexamethasone). In particular, integrins, chemokines, and adhesion molecules were overexpressed. These chemoresistant clones with a specific multi-flow signature also displayed genetic copy number alterations (CNA) that were present since diagnosis, and the resistant clone was selected after therapy resistance. The same group recently studied a larger number of patients ($n = 390$) in the PETHEMA/GEM2012MENOS65 protocol (six induction cycles with Bor, Lena, and dexamethasone followed by autologous stem cell transplant, two consolidation cycles with Bor, Lena, and dexamethasone, and then randomization to maintenance therapy with Lena and dexamethasone vs. Ixa, Lena, and dexamethasone)^[88]. They used NGF to identify detectable MRD and mechanisms related to resistance in 90 patients with high-risk (HR; i.e., del17p, t4;14, or t14;16) cytogenetics and 300 patients with standard-risk cytogenetics (SR; i.e., other anomalies not HR). Importantly, the results show the superiority of 90% PFS in MRD-negative patients vs. MRD-positive patients, irrespective of the cytogenetic status. Moreover, NGF studies and whole-genome sequencing showed clonal selection and higher genomic aberrations and mutations in 40 patients with multi-resistant clones^[94]. Most mutations affected *KRAS*, *BRAF*, *CCND1*, *ROS1*, *NRAS*, and *FLT3* genes. CNA and mutations present at diagnosis were more likely to disappear in SR-cytogenetics patients, while HR patients had novel mutations during treatment, suggesting more genomic instability. In addition, when evaluating transcriptional clones, patients with HR cytogenetics showed the expression of *PRDX6* and *SOD1*, which were related to a worst PFS. The authors concluded that, in HR cytogenetics MM patients, MRD resistance can arise from clones that evolve transcriptionally after therapy.

Minimal residual disease negativity after current upfront therapies for transplant and non-transplant eligible myeloma patients

With the introduction of novel drugs, responses can be seen in the majority of MM patients treated at diagnosis, both transplant and non-transplant eligible, with PFS lasting up to five years [Tables 2 and 3].

It is now evident that PFS alone cannot be the main parameter to judge new drugs in clinical trials. MRD has been proven to be a good prognosticator for PFS, OS, and drug resistance^[92]. In the GIMEMA-MMY-3006 study, VTD was compared to TD in 480 MM transplant eligible patients for induction therapy and double ASCT followed by consolidation therapy^[95]. VTD incorporated into a double ASCT strategy plus consolidation therapy proved to be superior to TD in terms of CR attained (58% vs. 41%, respectively) and PFS and OS at 10 years (34% vs. 17% and 60% vs. 46%, respectively)^[96]. Although MRD was not done at that time, one study showed that, in a subset of patients treated with VTD consolidation after ASCT, MRD negativity was achieved and relapses were delayed^[97]. In the IFM 2009, VRD was compared with VRD + ASCT, and in the latter group CR was superior (59% vs. 49%) but OS did not differ significantly^[98]. Importantly, MRD negativity was significantly correlated with improved three-year PFS (87% vs. 42%), independently of the therapy received. Car was combined with Len and dexamethasone in the KRd regimen tested as induction and consolidation + maintenance therapy for up to 10 cycles^[93,99]. Although relatively few patients were treated, MRD negativity was reached in a high percentage of patients. Recently, Dara was added to VTD and compared to VTD alone in 1085 patients in the CASSIOPEIA study^[13]: response and MRD negativity were superior in Dara-VTD vs. VTD (64% vs. 44%). Dara was added before

Table 2. CR and MRD results in transplant eligible patients with currently available therapy

Authors	Regimen	n	ASCT (NO/1/2)	C/M	CR (%)	MRD neg (%)	PFS/OS (months)
Cavo et al. ^[95]	TD	238	2	C + M	41	NA	40.7/110
	VTD	236			58		59.6/NR
Attal et al. ^[98]	VRD	350	NO	C + M	49	65	37/NR
	VRD	350	1		59	80	50/NR
Jasielec et al. ^[99]	KRD	76	1	C + M	78.9	70	NR
Moreau et al. ^[13]	Dara-VTD	543	1	C + M	39	64	NR
	VTD	542			26	44	
Voorhees et al. ^[100]	Dara-VRD	103	1	C + M	66	64	NR
Laubach et al. ^[101]	VRD	104			47	30	

PFS: Progression-free survival; OS: overall survival; CR: complete response; C + M: consolidation + maintenance; NA: not applicable; NR: not reached; ASCT: autologous stem cell transplantation; TD: thalidomide and dexamethasone; VTD: bortezomib, thalidomide, and dexamethasone; VRD: bortezomib, lenalidomide, and dexamethasone; KRD: carfilzomib, lenalidomide, and dexamethasone; Dara-VTD: daratumumab, bortezomib, thalidomide, and dexamethasone; Dara-VRD: daratumumab, bortezomib, lenalidomide, and dexamethasone.

Table 3. CR and MRD results in non-transplant eligible patients with currently available therapy

Authors	Regimen	n	CR (%)	MRD neg (%)	PFS/OS (months)
San Miguel et al. ^[102]	VMP	344	30	NA	24/56
	MP	338	4		16.6/43
Benboubker et al. ^[103]	RD cont.	535	15	NA	25.5/59
	RD18	541547	14		20.7/62
	MPT		9		21.2/49
Facon et al. ^[12]	Dara-RD	368	48	31	NR
	RD	369	25	10	34/NR
Mateos et al. ^[11]	Dara-VMP	356	46	28	36.4/NR
	VMP	350	25	7	19.3/NR
Durie et al. ^[105]	VRD	235	24.2	NA	41/NR
	RD	225	12.1		29/69

PFS: Progression-free survival; OS: overall survival; CR: complete response.

ASCT to VRD in the GRIFFIN study and then compared to VRD alone^[100,101]. Consolidation and maintenance therapy were also applied for up to 26 months of total therapy. MRD negativity was significantly superior in the Dara group (64% vs. 30%).

In the non-transplant eligible setting, great improvement with respect to the standard VMP or RD used until a few months ago^[102-104] was brought recently by the addition of daratumumab. The MAIA study^[12] compared Dara-Rd vs. Rd in MM patients not eligible for ASCT. At five years of follow-up, PFS has not been reached for the Dara-Rd group. CR was reached in 47% vs. 24% and MRD negativity was significantly higher (31% vs. 10%). The Alcyone trial^[11] compared VMP vs. Dara-VMP. This study confirmed the superiority of the triplet with Dara, in both PFS and MRD negativity. Lastly, VRD was superior to RD in the SWOGS0777 trial in patients not proceeding to ASCT (PFS 41 months vs. 29 months)^[105]. Daratumumab was tested as consolidation therapy in patients achieving a > VGPR after ASCT in the DART4MM study^[106,107]. An interim analysis showed MRD negativity in 45% of the patients at six months of treatment. Besides the great progress achieved with the new drugs with regard to the depth of responses, MRD status should not guide clinical decisions.

CONCLUSION

MM patients still relapse after a variable period of remission. Drug resistance is a major cause of MM relapse with both intrinsic and extrinsic mechanisms. Therapeutic targeting of the bone marrow microenvironment and its interaction with MM plasma cells seems to be an ideal approach for the future. Besides the need for novel, more efficacious drugs, better prognosticators are also needed. MRD measured by NGF or NGS has entered into the MM diagnostic armamentarium and is a great prognosticator for novel drugs in clinical trials. Sustained MRD negativity is likely to be a long-term remission pre-requisite. Research has to be done to better clarify its role in identifying minimal residual sub-clones resistant to drugs commonly utilized in MM. NGF seems promising in this biological view. The characterization of these clones should be pursued in future large MM trials.

DECLARATIONS

Authors' contributions

Made substantial contributions to conception and design of the study: Gozzetti A, Pacelli P, Raspadori D, Tocci D

Wrote the manuscript: Gozzetti A, Ciofini S, Sicuranza A, Cencini E

Supervised the manuscript: Bocchia M

Availability of data and materials

Not applicable.

Financial support and sponsorship

None.

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2022.

REFERENCES

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. *Blood* 2008;111:2516-20. DOI PubMed PMC
2. Brenner H, Gonds A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. *Blood* 2008;111:2521-6. DOI PubMed
3. Gozzetti A, Candi V, Papini G, Bocchia M. Therapeutic advancements in multiple myeloma. *Front Oncol* 2014;4:241. DOI PubMed PMC
4. Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). *Leukemia* 2014;28:525-42. DOI PubMed PMC
5. Gozzetti A, Cerase A. Novel agents in CNS myeloma treatment. *Cent Nerv Syst Agents Med Chem* 2014;14:23-7. DOI PubMed
6. Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. *Blood* 2016;128:37-44. DOI PubMed
7. Jurczynszyn A, Olszewska-Szopa M, Hungria V, et al. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. *Leuk Lymphoma* 2016;57:2071-6. DOI PubMed
8. Kocoglu MH, Badros AZ. Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond. *Expert Rev Hematol* 2020;13:669-86. DOI PubMed

9. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. *Blood* 2017;130:974-81. [DOI PubMed](#)
10. Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. *Lancet Oncol* 2021;22:801-12. [DOI PubMed](#)
11. Mateos M, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. *Lancet* 2020;395:132-41. [DOI PubMed](#)
12. Facon T, Kumar S, Plesner T, et al; MAIA Trial Investigators. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. *N Engl J Med* 2019;380:2104-15. [DOI PubMed](#)
13. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet* 2019;394:29-38. [DOI PubMed](#)
14. Mohty M, Terpos E, Mateos MV, et al; EMMOS Investigators. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. *Clin Lymphoma Myeloma Leuk* 2018;18:e401-19. [DOI PubMed](#)
15. Gozzetti A, Cerase A, Lotti F, et al; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Myeloma Working Party. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. *Cancer* 2012;118:1574-84. [DOI PubMed](#)
16. Castillo JJ, Jurczyszyn A, Brozova L, et al. IgM myeloma: a multicenter retrospective study of 134 patients. *Am J Hematol* 2017;92:746-51. [DOI PubMed](#)
17. Jurczyszyn A, Radocha J, Davila J, et al. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. *Br J Haematol* 2018;180:831-9. [DOI PubMed](#)
18. Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. *Blood Cancer J* 2015;5:e365. [DOI PubMed PMC](#)
19. Gozzetti A, Le Beau MM. Fluorescence in situ hybridization: uses and limitations. *Semin Hematol* 2000;37:320-33. [DOI PubMed](#)
20. Goldman-Mazur S, Jurczyszyn A, Castillo JJ, et al. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. *Am J Hematol* 2020;95:503-9. [DOI PubMed](#)
21. Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. *Blood* 2012;120:1067-76. [DOI PubMed PMC](#)
22. Davis LN, Sherbenou DW. Emerging therapeutic strategies to overcome drug resistance in multiple myeloma. *Cancers (Basel)* 2021;13:1686. [DOI PubMed PMC](#)
23. Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. *Blood* 2015;125:3059-68. [DOI PubMed PMC](#)
24. Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. *Leukemia* 2017;31:2094-103. [DOI PubMed PMC](#)
25. Romano A, Palumbo GA, Parrinello NL, Conticello C, Martello M, Terragna C. Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives. *Front Oncol* 2019;9:699. [DOI PubMed PMC](#)
26. Gozzetti A, Raspadori D, Bacchiari F, et al. Minimal residual disease in multiple myeloma: state of the art and applications in clinical practice. *J Pers Med* 2020;10:120. [DOI PubMed PMC](#)
27. Rawstron AC, Orfao A, Beksac M, et al; European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. *Haematologica* 2008;93:431-8. [DOI PubMed](#)
28. Brooimans RA, Kraan J, van Putten W, Cornelissen JJ, Löwenberg B, Gratama JW. Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination. *Cytometry B Clin Cytom* 2009;76:18-26. [DOI PubMed](#)
29. Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. *Am J Clin Pathol* 2009;132:728-32. [DOI PubMed](#)
30. Delgado JA, Guillén-Grima F, Moreno C, et al. A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates. *J Immunol Methods* 2017;442:54-8. [DOI PubMed](#)
31. Loken MR, Chu SC, Fritschle W, Kalnoski M, Wells DA. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. *Cytometry B Clin Cytom* 2009;76:27-36. [DOI PubMed](#)
32. Yanamandra U, Kumar SK. Minimal residual disease analysis in myeloma - when, why and where. *Leuk Lymphoma* 2018;59:1772-84. [DOI PubMed PMC](#)
33. Bai Y, Orfao A, Chim CS. Molecular detection of minimal residual disease in multiple myeloma. *Br J Haematol* 2018;181:11-26. [DOI PubMed](#)
34. Yao Q, Bai Y, Orfao A, Chim CS. Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma. *Front Oncol* 2019;9:449. [DOI PubMed PMC](#)
35. Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. *Blood* 2018;132:2456-64. [DOI PubMed PMC](#)
36. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol* 2016;17:e328-46. [DOI PubMed](#)
37. Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival

- outcomes in patients with multiple myeloma. *Blood Adv* 2020;4:5988-99. DOI PubMed PMC
38. Berger N, Kim-Schulze S, Parekh S. Minimal residual disease in multiple myeloma: impact on response assessment, prognosis and tumor heterogeneity. *Adv Exp Med Biol* 2018;1100:141-59. DOI PubMed
 39. Chauhan D, Hideshima T, Mitsiades C, et al. Proteasome inhibitor therapy in multiple myeloma. *Mol Cancer Ther* 2005;4:686-92. DOI PubMed
 40. Gozzetti A, Papini G, Candi V, Brambilla CZ, Sirianni S, Bocchia M. Second generation proteasome inhibitors in multiple myeloma. *Anticancer Agents Med Chem* 2017;17:920-6. DOI PubMed
 41. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. *Cell* 1994;79:13-21. DOI PubMed
 42. Barrio S, Stühmer T, Da-Viá M, et al. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. *Leukemia* 2019;33:447-56. DOI PubMed
 43. Robak P, Drozd I, Szemraj J, Robak T. Drug resistance in multiple myeloma. *Cancer Treat Rev* 2018;70:199-208. DOI PubMed
 44. Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. *Cancer Cell* 2013;24:289-304. DOI PubMed PMC
 45. Abraham J, Salama NN, Azab AK. The role of P-glycoprotein in drug resistance in multiple myeloma. *Leuk Lymphoma* 2015;56:26-33. DOI PubMed
 46. Besse A, Stolze SC, Rasche L, et al. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. *Leukemia* 2018;32:391-401. DOI PubMed PMC
 47. O'Connor R, Ooi MG, Meiller J, et al. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. *Cancer Chemother Pharmacol* 2013;71:1357-68. DOI PubMed PMC
 48. Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. *J Cell Mol Med* 2014;18:947-61. DOI PubMed PMC
 49. Baranowska K, Misund K, Starheim KK, et al. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells. *Oncotarget* 2016;7:70845-56. DOI PubMed PMC
 50. Xu H, Han H, Song S, et al. Exosome-transmitted PSMA3 and PSMA3-AS1 promote proteasome inhibitor resistance in multiple myeloma. *Clin Cancer Res* 2019;25:1923-35. DOI PubMed
 51. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. *Blood* 2006;107:1092-100. DOI PubMed PMC
 52. Kuhn DJ, Berkova Z, Jones RJ, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. *Blood* 2012;120:3260-70. DOI PubMed PMC
 53. Stessman HA, Baughn LB, Sarver A, et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. *Mol Cancer Ther* 2013;12:1140-50. DOI PubMed PMC
 54. Richardson P, Hideshima T, Anderson K. Thalidomide in multiple myeloma. *Biomed Pharmacother* 2002;56:115-28. DOI PubMed
 55. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. *Leukemia* 2012;26:2326-35. DOI PubMed PMC
 56. Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. *Nat Struct Mol Biol* 2014;21:803-9. DOI PubMed
 57. Hu S, Yuan L, Yan H, Li Z. Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor. *Bioorg Med Chem Lett* 2017;27:4075-81. DOI PubMed
 58. Kortüm KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. *Blood* 2016;128:1226-33. DOI PubMed PMC
 59. Bertrand E, Jouy N, Manier S, et al. Role of IRF4 in resistance to immunomodulatory (IMiD) compounds® in Waldenström's macroglobulinemia. *Oncotarget* 2017;8:112917-27. DOI PubMed PMC
 60. Haertle L, Barrio S, Munawar U, et al. Cereblon enhancer methylation and IMiD resistance in multiple myeloma. *Blood* 2021;138:1721-6. DOI PubMed PMC
 61. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. *N Engl J Med* 2015;373:1207-19. DOI PubMed
 62. Dimopoulos MA, Oriol A, Nahi H, et al; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med* 2016;375:1319-31. DOI PubMed
 63. Palumbo A, Chanan-Khan A, Weisel K, et al; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med* 2016;375:754-66. DOI PubMed
 64. Lonial S, Dimopoulos M, Palumbo A, et al; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. *N Engl J Med* 2015;373:621-31. DOI PubMed
 65. Dimopoulos M, Quach H, Mateos M, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. *Lancet* 2020;396:186-97. DOI PubMed
 66. Nijhof IS, Casneuf T, van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. *Blood* 2016;128:959-70. DOI PubMed
 67. Varga C, Maglio M, Ghobrial IM, Richardson PG. Current use of monoclonal antibodies in the treatment of multiple myeloma. *Br J Haematol* 2018;181:447-59. DOI PubMed
 68. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing

- of multiple myeloma and other hematological tumors. *J Immunol* 2011;186:1840-8. DOI PubMed
69. Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. *MAbs* 2015;7:311-21. DOI PubMed PMC
70. Pick M, Vainstein V, Goldschmidt N, et al. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. *Eur J Haematol* 2018;100:494-501. DOI PubMed
71. Cho SF, Lin L, Xing L, et al. BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma. *Cancers (Basel)* 2020;12:1473. DOI PubMed PMC
72. Nijhof IS, Groen RW, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. *Leukemia* 2015;29:2039-49. DOI PubMed
73. Gupta VA, Matulis SM, Conage-Pough JE, et al. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. *Blood* 2017;129:1969-79. DOI PubMed PMC
74. Ria R, Vacca A. Bone marrow stromal cells-induced drug resistance in multiple myeloma. *Int J Mol Sci* 2020;21:613. DOI PubMed PMC
75. Cencini E, Fabbri A, Sicuranza A, Gozzetti A, Bocchia M. The role of tumor-associated macrophages in hematologic malignancies. *Cancers (Basel)* 2021;13:3597. DOI PubMed PMC
76. Beider K, Bitner H, Leiba M, et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. *Oncotarget* 2014;5:11283-96. DOI PubMed PMC
77. Zheng Y, Cai Z, Wang S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. *Blood* 2009;114:3625-8. DOI PubMed PMC
78. Zheng Y, Yang J, Qian J, et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. *Leukemia* 2013;27:702-10. DOI PubMed PMC
79. Kim J, Denu RA, Dollar BA, et al. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. *Br J Haematol* 2012;158:336-46. DOI PubMed PMC
80. Scavelli C, Nico B, Cirulli T, et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. *Oncogene* 2008;27:663-74. DOI PubMed
81. Ribatti D, Vacca A. The role of monocytes-macrophages in vasculogenesis in multiple myeloma. *Leukemia* 2009;23:1535-6. DOI PubMed
82. De Beule N, De Veirman K, Maes K, et al. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation. *J Pathol* 2017;241:534-46. DOI PubMed
83. Cencini E, Fabbri A, Bocchia M. Prognostic role of M2 tumour-associated macrophages in lymphoproliferative disorders. *J Pathol* 2017;242:511-2. DOI PubMed
84. Wang H, Hu WM, Xia ZJ, et al. High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. *J Cancer* 2019;10:3239-45. DOI PubMed PMC
85. Andersen MN, Andersen NF, Rødgaard-Hansen S, Hokland M, Abildgaard N, Møller HJ. The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): implications in multiple myeloma. *Leuk Res* 2015;39:971-5. DOI PubMed
86. Suyani E, Sucak GT, Akyürek N, et al. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. *Ann Hematol* 2013;92:669-77. DOI PubMed
87. Chen X, Chen J, Zhang W, et al. Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma. *Oncotarget* 2017;8:112685-96. DOI PubMed PMC
88. Panchabhai S, Kelemen K, Ahmann G, Sebastian S, Mantei J, Fonseca R. Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma. *Leukemia* 2016;30:951-4. DOI PubMed
89. Andersen MN, Abildgaard N, Maniecki MB, Møller HJ, Andersen NF. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. *Eur J Haematol* 2014;93:41-7. DOI PubMed
90. Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. *Clin Cancer Res* 2016;22:5428-33. DOI PubMed PMC
91. Lionetti M, Neri A. Utilizing next-generation sequencing in the management of multiple myeloma. *Expert Rev Mol Diagn* 2017;17:653-63. DOI PubMed
92. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. *JAMA Oncol* 2017;3:28-35. DOI PubMed PMC
93. Paiva B, Corchete LA, Vidriales MB, et al; Spanish Myeloma Group/Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Groups. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. *Blood* 2016;127:1896-906. DOI PubMed
94. Goicoechea I, Puig N, Cedena MT, et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. *Blood* 2021;137:49-60. DOI PubMed
95. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet* 2010;376:2075-85. DOI PubMed
96. Tacchetti P, Pantani L, Patriarca F, et al. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. *Lancet Haematology* 2020;7:e861-73. DOI PubMed

97. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. *J Clin Oncol* 2010;28:2077-84. [DOI](#) [PubMed](#)
98. Attal M, Lauwers-Cances V, Hulin C, et al; IFM 2009 Study. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. *N Engl J Med* 2017;376:1311-20. [DOI](#) [PubMed](#)
99. Jasielc JK, Kubicki T, Raje N, et al. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. *Blood* 2020;136:2513-23. [DOI](#) [PubMed](#) [PMC](#)
100. Voorhees PM, Rodriguez C, Reeves B, et al. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. *Blood Adv* 2021;5:1092-6. [DOI](#) [PubMed](#) [PMC](#)
101. Laubach JP, Kaufman JL, Sborov DW, et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of griffin after 24 months of maintenance. *Blood* 2021;138:79. [DOI](#)
102. San Miguel JF, Schlag R, Khuageva NK, et al; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med* 2008;359:906-17. [DOI](#) [PubMed](#)
103. Benboubker L, Dimopoulos MA, Dispenzieri A, et al; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med* 2014;371:906-17. [DOI](#) [PubMed](#)
104. Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. *Blood* 2018;131:301-10. [DOI](#) [PubMed](#) [PMC](#)
105. Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). *Blood Cancer J* 2020;10:53. [DOI](#) [PubMed](#) [PMC](#)
106. Gozzetti A, Raspadori D, Bacchiari F, et al. DART4MM: daratumumab as consolidation therapy in patients who already achieved optimal response/MRD positivity by next generation flow (NGF): preliminary results of a phase 2 multicenter study. *Clin Lymphoma Myeloma Leuk* 2019;19:e161-2. [DOI](#)
107. Gozzetti A, Bacchiari F, Sammartano V, et al. Long-term safety of rapid daratumumab infusions in multiple myeloma patients. *Front Oncol* 2020;10:570187. [DOI](#) [PubMed](#) [PMC](#)